Haematological Malignancies: management of lymphoid and myeloid leukaemia
01 - 02 Jun 2009
London
Book online here, alternatively call our credit card hotline 020 7501 6762.
To request an invoice, download and complete the pdf booking form stating your invoicing address and return via fax or post.
Cheque payments should be made payable to MA Healthcare Ltd and posted with a completed booking form.
Details
Monday 1st June 2009
| 08.00 – 08.55 | Registration and refreshments |
| 08.55 – 09.00 | Welcome & introduction |
| ALL | |
| 09.00-09.30 | Improving the outlook for adult ALL Dr Matthew Smith Consultant Haematologist Guy’s and St Thomas’ NHS Foundation Trust |
| 09.30-10.00 | New prognostic indicators and minimal residual disease markers Dr Nick Goulden Consultant in Paediatric Haematology Great Ormond Street Hospital, London |
| 10.00-10.30 | Treatment of mature B-ALL and B-lymphoblastic lymphomas Dr Robert Carr Consultant and Honorary Senior Lecturer in Clinical and Laboratory Haematology Guy’s and St Thomas’ NHS Foundation Trust, London |
| 10.30-10.40 | Discussion |
| 10.40-11.00 | Refreshments |
| CLL | |
| 11.00-11.20 | Identification of markers for predicting disease progression Dr Chris Pepper Senior Lecturer Cardiff University |
| 11.20-11.40 | The role of c-Abl in the pathogenesis of CLL Dr Ke Lin Clinical Scientist University of Liverpool |
| 11.40-12.00 | Managing the complications Professor Terry Hamblin Professor of Immunohaematology, University of Southampton & Honorary Consultant, Royal Bournemouth Hospital |
| 12.00-12.20 | Current combination chemotherapies Dr Claire Dearden Consultant Haematologist Institute for Cancer Research and Royal Marsden Hospital, London |
| 12.20-12.30 | Discussion |
| 12.30-13.20 | Lunch |
| AML | |
| 13.20-13.50 | Progress in identifying molecular targets in AML Professor David Grimwade Professor of Molecular Haematology King’s College London |
| 13.50-14.20 | Treatment options in the elderly Professor Alan Burnett Professor of Haematology University of Wales College of Medicine, Cardiff |
| 14.20-14.50 | Management of relapsed and refractory AML Professor Mary Frances McMullin Professor of Clinical Haematology and Consultant Haematologist Belfast City Hospital |
| 14.50-15.00 | Discussion |
| 15.00-15.20 | Refreshments |
| CML | |
| 15.20-15.40 | Diagnosis, disease phase and prognosis Dr Graeme Smith Consultant Haematologist and Clinical Director St James’ University Hospital, Leeds |
| 15.40-16.00 | First-line therapies for children and adults in chronic stage Dr David Marin Senior Lecturer and Honorary Consultant Imperial College London |
| 16.00-16.20 | Mechanisms of treatment-resistance to CML Professor Richard Clark Professor of Haematology and Consultant Haematologist Royal Liverpool University Hospital |
| 16.20-16.40 | Second generation tyrosine kinase inhibitors Professor John Goldman Consultant Haematologist Hammersmith Hospital, London |
| 16.40-17.00 | Discussion |
| 17.00 | Close of Day One |
Tuesday 2nd June 2009
| 08.30-09.00 | Registration and refreshments |
| Promising new treatments | |
| 09.00-09.30 | Role of targeted immunoradiotherapy Dr Peter Nicholls Senior Lecturer in Cell and Molecular Biology University of Kent |
| 09.30-10.00 | New treatments for acute leukaemia Dr Brenda Gibson Consultant Haematologist, Royal Hospital for Sick Children, Glasgow & President of the British Society of Haematology |
| 10.00-10.30 | Clinical trial updates of emerging immunotherapies Professor Hans Stauss Professor of Clinical Immunology Royal Free and University College Medical School, London |
| 10.30-10.40 | Discussion |
| 10.40-11.00 | Refreshments and exhibition viewing |
| 11.00-11.30 | Novel monoclonal antibody treatments Dr Estella Matutes Reader in Haematological Malignancies, Institute of Cancer Research & Consultant Haematologist, Royal Marsden Hospital, London |
| 11.30-12.00 | Gene therapies: potential of RNA interference technology Dr Elena Vigorito Group Leader The Babraham Institute, Cambridge |
| 12.00-12.30 | Developments in overcoming drug resistance Dr Elaine Willmore Senior Research Associate Northern Institute for Cancer Research, Newcastle University |
| 12.30-12.40 | Discussion |
| 12.40-13.30 | Lunch and exhibition viewing |
| Transplantation | |
| 13.30-14.00 | Value of stem cell transplants in lymphoid and myeloid leukaemias Professor Stephen McKinnon Professor in Haematology Royal Free and University College Medical School, London |
| 14.00-14.30 | Alternative donors and cord blood transplantation Dr Bronwen Shaw Institute Fellow, Institute of Cancer Research & Honorary Consultant, Royal Marsden Hospital, London |
| 14.30-14.40 | Discussion |
| 14.40-15.00 | Refreshments |
| 15.00-15.30 | The role of reduced-intensity conditioning transplants Dr Gordon Cook Director, Blood and Bone Marrow Transplantation & Consultant Haematologist, St James’s University Hospital, Leeds |
| 15.30-16.00 | Progress in the prevention of GvHD Dr Matthew Collin Senior Lecturer and Honorary Consultant Newcastle University |
| 16.00-16.30 | Relapse monitoring and management post-transplant Dr Prem Mahendra Consultant Haemato-oncologist University Hospital Birmingham NHS Foundation Trust |
| 16.30-16.45 | Discussion and closing remarks |
| 16.45 | Close of conference |
Book online
Book and pay securely online
Download pdf programme
Download a pdf programme of the conference
Download venue info
Download a pdf for venue information
View accomodation info
View accomodation information